SCHEMBL3468337

SCHEMBL3468337

O=C1c2ccccc2C(=O)N1CCCCCCCCCCCCCCO

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.70
ALDH1A1 P00352 2/20 0.70
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
RGS12 O14924 1/20 0.70
NPC1 O15118 1/20 0.70
LMNA P02545 1/20 0.70
PABPC1 P11940 1/20 0.70
HTT P42858 1/20 0.70
RECQL P46063 1/20 0.70
RAB9A P51151 1/20 0.70
TDP1 Q9NUW8 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
HDAC8 Q9BY41 3/20 0.61
HDAC3 O15379 2/20 0.61
HDAC4 P56524 2/20 0.61
HDAC1 Q13547 2/20 0.61
HDAC7 Q8WUI4 2/20 0.61
HDAC2 Q92769 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7544499 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7352888 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7285741 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7296911 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4179085 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17275126 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1448490 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1162502 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3468673 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1703575 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
US-20250214969-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
EP-4499149-A1 PROTEIN DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-02-05 EP disclosed
WO-2024220937-A2 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-10-24 WO disclosed
WO-2023192578-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
WO-2023192578-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
EP-2261662-B1 Novel synthetic blocking reagents FORSCHUNGSZENTRUM BORSTEL LEIBNIZ ZENTRUM FUER MEDIZIN UND BIOWISSENSCHAFTEN (DE) 2014-01-22 EP disclosed
US-8501199-B2 Synthetic blocking reagents FORSCHUNGSZENTRUM BORSTEL (DE) 2013-08-06 US disclosed
US-20100317048-A1 NOVEL SYNTHETIC BLOCKING REAGENTS FORSCHUNGSZENTRUM BORSTEL (DE) 2010-12-16 US disclosed
EP-2261662-A1 Novel synthetic blocking reagents Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften (DE) 2010-12-15 EP disclosed
EP-0885886-B1 PYRIDINECARBOXAMIDE DERIVATIVES NISSHIN SEIFUN GROUP INC (JP) 2002-05-29 EP disclosed
US-5972943-A N-(NITRIC ACID,C14-18 ALKYL ESTER)-6-(1-(OPTIONALLY 4-SUBSTITUTED PIPERAZINYL)) PYRIDINE-3-CARBOXAMIDES; METHOD OF SYNTHESIS; ADMINISTERING TO TREAT CEREBRAL EDEMA; NO HYPOTENSIVE SIDE EFFECT NISSHIN FLOUR MILLING CO., LTD. (JP) 1999-10-26 US disclosed
EP-0885886-A1 NOVEL PYRIDINECARBOXAMIDE DERIVATIVES Nisshin Flour Milling Co., Ltd. (JP) 1998-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 KDM4E 810/4885ALDH1A1 3930/4885MEN1 4258/4885
US-20100317048-A1 NOVEL SYNTHETIC BLOCKING REAGENTS SPR, SSB, LY96 KDM4E 1490/4885ALDH1A1 3115/4885MEN1 4078/4885
US-20250214969-A1 PROTEIN DEGRADERS AND USES THEREOF MDM2, CUL1, PSMG3 KDM4E 935/4885ALDH1A1 3843/4885MEN1 2643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.